RARE news & sentiment — Ultragenyx Pharmaceutical Inc.

MAY 21·Investing.com CanadaHigh

Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook By Investing.com

Cantor Fitzgerald has increased its price target for Ultragenyx Pharma (NASDAQ: RARE) to $96 from $84, maintaining an Overweight rating. This adjustment follows increased confidence in GTX-102, a treatment for Angelman syndrome, with its probability of success raised to 60%. Despite recent financial misses for Q1 2026, the company reaffirmed its full-year revenue guidance and recently elected three Class I directors.

MAY 18·Stock Titan

[Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading Activity

This article details an insider trading activity at Ultragenyx Pharmaceutical Inc. (RARE), specifically a Form 4 filing by director Daniel G. Welch. Welch reported receiving 7,751 shares of common stock as restricted stock units and a stock option for 14,058 shares, with both vesting fully by the company's next Annual Meeting of Stockholders or May 14, 2027. The filing indicates a neutral impact and sentiment regarding these transactions.

APR 3·Stock Titan

Ultragenyx (RARE) CFO sells 4,683 shares, retains 80,351 stake

Ultragenyx Pharmaceutical Inc.'s CFO, Howard Horn, sold 4,683 shares of common stock at $20.97 per share in an open-market transaction. Following this sale, Horn directly holds 80,351 shares, which include restricted stock units. This transaction was disclosed in a Form 4 filing and is part of a 10b5-1 plan.

$RARE

Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook By Investing.com

[Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading Activity

Ultragenyx (RARE) CFO sells 4,683 shares, retains 80,351 stake

News on $RARE